

# DNlite-IVD103

novel diagnostic solution for precision management of DKD

- Accurately differentiate progressive decliners of renal function in T2DM
- Risk assessment of renal complications in diabetic patients

## **Non-invasive Urinary ELISA Test**

Perfect for clinical practice

Predict progressive decliner  
**months to years earlier**

Risk Assessment for  
**Predicting & Monitoring Renal Function Loss**

**Precision DKD Management**  
& Complementary Test

**Proven Quality**  
CE IVD Marked / ISO13485 & GMP



# Diabetic Kidney Diseases (DKD) is the leading cause of end-stage renal disease (ESRD)

With 40% of diabetic patients worldwide (nearly half-a-billion) developing kidney complications, it has never been more critical to shift from diagnosis to prevention<sup>i</sup>.

- ▶ DKD Shortens Life Span by 16 years<sup>ii</sup>
- ▶ 5-year survival rate of an ESRD from DKD is less than 50%<sup>iii</sup>
- ▶ CKD causes huge healthcare burden<sup>iv</sup>

## Unmet Need: Lack of True Diagnostic Gold Standard


Urine albumin to creatinine ratio (UACR) and estimated Glomerular Filtration Rate (eGFR), but they cannot meet the required sensitivity and specificity to predict and identify DKD patients who will progress. DKD patients with microalbuminuria are difficult to manage due to unsatisfactory correlation with Albuminuria<sup>v</sup>. eGFR is a late biomarker<sup>vi</sup> and diseases can progress years without apparent symptoms<sup>vii</sup>.



- ▶ UACR: Cannot meet the required sensitivity and specificity
- ▶ Many patients with Micro-Albuminuria revert to Normal Albuminuria
- ▶ Patients may also progress to kidney failure from Normal or Micro-Albuminuria

## DNlite-IVD103

DNlite-IVD103 is a urinary ELISA kit that precisely manages DKD. By detecting and monitoring a unique biomarker with specific post translational modification (PTM), DNlite-IVD103 can effectively predict the kidney condition of a diabetic patient over the 1-2 years that follow



### Reference

- United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020 Clin J Am Soc Nephrol 2017; 12(12): 2032-2045.
- Kidney Int 2017; 92(2):388-396.
- Clin Kidney J 2016; 9(6): 833-838.
- United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020.
- J Clin Med. 2015; 4(9): 1761-1773.
- Kidney Int Supp. 2013; 3, 1-150.
- J Clin Invest 2006; 116(2): 288-296.



### About BPM

Bio Preventive Medicine (BPM) is a leading company in renal biomarker area. As a clinical staged IVD and biotech company, BPM focuses on translating validated and IP-protected novel biomarkers into diagnostic solutions for unmet clinical needs. For more information, please refer to BPM official website or contact us.

Bio Preventive Medicine Corp.

<http://www.bpmbiotech.com/>

E-mail: [dnlite@bpmbiotech.com](mailto:dnlite@bpmbiotech.com)

Address: 6F-1, No.18, Taiyuan St., Zhubei City, Hsinchu County 302, Taiwan